Niclosamide | Jotup

Danish biotech UNION adds program to prevent COVID-19 with intranasal delivery of niclosamide

Retrieved on:

Wednesday, October 21, 2020

Medical specialties, RTT, Health, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Medicine, Coronavirus disease, Vaccine

HELLERUP, Denmark, Oct. 21, 2020 /PRNewswire/ -- UNION therapeutics A/S (UNION) announces expansion of the clinical pipeline with the addition of UNI91103 (intranasal niclosamide) to prevent COVID-19 and reduce the severity of the diseases among those already infected.

Key Points:

HELLERUP, Denmark, Oct. 21, 2020 /PRNewswire/ -- UNION therapeutics A/S (UNION) announces expansion of the clinical pipeline with the addition of UNI91103 (intranasal niclosamide) to prevent COVID-19 and reduce the severity of the diseases among those already infected.
Several high-risk patient groups do not respond well to vaccination suggesting a persistent need for alternative prophylactic measures.
In response, UNION has expanded its clinical program for COVID-19 with a niclosamide based nasal spray (UNI91103) to prevent and alleviate infection among people at risk.
Furthermore, niclosamide has been demonstrated to prevent fatal outcomes in a murine model of COVID-19 when administered intranasally2.

Danish biotech UNION adds program to prevent COVID-19 with intranasal delivery of niclosamide

Retrieved on:

Wednesday, October 21, 2020

Medical specialties, RTT, Health, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Medicine, Coronavirus disease, Vaccine

HELLERUP, Denmark, Oct. 21, 2020 /PRNewswire/ -- UNION therapeutics A/S (UNION) announces expansion of the clinical pipeline with the addition of UNI91103 (intranasal niclosamide) to prevent COVID-19 and reduce the severity of the diseases among those already infected.

Key Points:

HELLERUP, Denmark, Oct. 21, 2020 /PRNewswire/ -- UNION therapeutics A/S (UNION) announces expansion of the clinical pipeline with the addition of UNI91103 (intranasal niclosamide) to prevent COVID-19 and reduce the severity of the diseases among those already infected.
Several high-risk patient groups do not respond well to vaccination suggesting a persistent need for alternative prophylactic measures.
In response, UNION has expanded its clinical program for COVID-19 with a niclosamide based nasal spray (UNI91103) to prevent and alleviate infection among people at risk.
Furthermore, niclosamide has been demonstrated to prevent fatal outcomes in a murine model of COVID-19 when administered intranasally2.

UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.

Retrieved on:

Thursday, August 13, 2020

RTT, Anthelmintics, Chloroarenes, Salicylanilides, Niclosamide, Nitrobenzenes, Chemical substances, Chemistry

For a number of years, UNION has worked with niclosamide as a potential treatment for a range of inflammatory and infectious diseases.

Key Points:

For a number of years, UNION has worked with niclosamide as a potential treatment for a range of inflammatory and infectious diseases.
Under the agreement, UNION will acquire an option to obtain a worldwide exclusive license to the technology and rights relating to the formulations of niclosamide for the treatment of COVID-19.
UNION is already progressing the niclosamide-based product UNI911through clinic development, and the agreement with TFF has the potential to substantially broaden UNION's niclosamide product offering.
We are excited to formalize our collaboration with the TFF team and consolidate our joint efforts under the wings of UNION.

UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.

Retrieved on:

Thursday, August 13, 2020

RTT, Anthelmintics, Chloroarenes, Salicylanilides, Niclosamide, Nitrobenzenes, Chemical substances, Chemistry

For a number of years, UNION has worked with niclosamide as a potential treatment for a range of inflammatory and infectious diseases.

Key Points:

For a number of years, UNION has worked with niclosamide as a potential treatment for a range of inflammatory and infectious diseases.
Under the agreement, UNION will acquire an option to obtain a worldwide exclusive license to the technology and rights relating to the formulations of niclosamide for the treatment of COVID-19.
UNION is already progressing the niclosamide-based product UNI911through clinic development, and the agreement with TFF has the potential to substantially broaden UNION's niclosamide product offering.
We are excited to formalize our collaboration with the TFF team and consolidate our joint efforts under the wings of UNION.

ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19

Retrieved on:

Tuesday, August 11, 2020

ANA Therapeutics , a Silicon Valley-based biotech startup, and Quotient Sciences , a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19.

Key Points:

ANA Therapeutics , a Silicon Valley-based biotech startup, and Quotient Sciences , a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19.
We have selected Quotient Sciences as our development and manufacturing partner and our plan is simple, said Andrew Bartynski , COO, ANA Therapeutics.
Mark Egerton, Ph.D. , CEO of Quotient Sciences, said, We are proud to partner with ANA Therapeutics in their pursuit of a treatment to fight this coronavirus pandemic.
ANA Therapeutics is a Silicon Valley-based biotech startup working to develop niclosamide as a safe, widely accessible antiviral treatment for patients with COVID-19.

ANA Therapeutics Announces U.S. FDA Clearance Of IND Application To Initiate Clinical Trial Of Niclosamide In COVID-19 Patients

Retrieved on:

Tuesday, August 4, 2020

Health, Articles, Clinical research, Pharmaceutical industry, Drug discovery, Clinical pharmacology, RTT, Coronavirus disease, Clinical trial, Niclosamide

ANA will evaluate both the safety of niclosamide as well as its ability to show a clinical improvement in hospitalized patients with COVID-19.

Key Points:

ANA will evaluate both the safety of niclosamide as well as its ability to show a clinical improvement in hospitalized patients with COVID-19.
During the trial, patients will be given a seven-day course of niclosamide and monitored for 60 days.
This will be the first U.S.- based clinical trial to determine the efficacy of niclosamide in COVID-19," ANA Co-Founder and CEO Akash Bakshi said.
Therefore, ANA Therapeutics believes niclosamide has the strong potential to both stop viral replication and reduce symptoms in patients suffering from COVID-19.

UNION Receives Approval From Danish Medicines Agency to Initiate Clinical Study With Niclosamide for Treatment of COVID-19

Retrieved on:

Wednesday, July 1, 2020

Health, Drug discovery, Chloroarenes, Niclosamide, Nitrobenzenes, RTT, Salicylanilides, Clinical trial, Severe acute respiratory syndrome-related coronavirus

Over a number of years, UNION has built a deep understanding of niclosamide and its mechanism of action.

Key Points:

Over a number of years, UNION has built a deep understanding of niclosamide and its mechanism of action.
The extensive experience and data generated to date by UNION with niclosamide, and in particular optimized salt forms thereof, have enabled rapid progress leading to the successful approval of the Clinical Trial Application".
CEO and Co-founder of UNION, Dr. Rasmus Toft-Kehler concludes: "UNION has been through an amazing period of process leading to approval of the Clinical Trial Application.
Niclosamide has the potential to become a truly differentiated treatment of COVID-19, effectively blocking replication of SARS-CoV-2 by targeting host cells to disrupt the viral life cycle.

TFF Pharmaceuticals’ Inventor Dr. Robert O. Williams III Presents Session on Repurposing Niclosamide for COVID-19 Treatment at AAPS Meeting

Retrieved on:

Thursday, April 30, 2020

Dr. Williams and co-author Dr. Zachary N. Warnken presented data focusing on repurposing the existing antiviral drug, niclosamide, in a session titled, Leveraging Repurposed Drugs An Activity that Must be Exhausted.

Key Points:

Dr. Williams and co-author Dr. Zachary N. Warnken presented data focusing on repurposing the existing antiviral drug, niclosamide, in a session titled, Leveraging Repurposed Drugs An Activity that Must be Exhausted.
Successful repurposing would need a mechanism for overcoming the inherent delivery issues posed by this low absorption and bioavailability.
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.
TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements.